Biopharma Market’s Green Shoots Are Evident But Full Recovery Must Wait Awhile

Learning To Weather Tough Times Can Deliver Valuable Long-Term Benefits

Biopharma markets may follow the downward trajectory of tech during tough times, but they also chase it back up the value curve. Recovery is just a matter of time, says Seventure’s Isabelle de Crémoux in this commentary on investment trends, the financial markets and the VC environment.

The French biopharma industry is riding a wave of confidence in the wake of the May decisions by Sanofi, Pfizer Inc., AstraZeneca PLC and GSK plc collectively to invest over $2bn in local biopharma research and manufacturing.

The news was swiftly followed by Sanofi announcing it would allocate €100m ($105m) of its investment to expand its...

More from Market Intelligence

More from In Vivo